Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 7/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29142179 | 1.00 | POLB (0.36) | POLBPEPDMMP2ANPEPCYP1A2 | |
| SCHEMBL20221261 | 0.82 | POLB (0.37) | POLBPEPDMMP2ANPEPCYP1A2 | |
| SCHEMBL22211398 | 0.80 | PEPD (0.37) | POLBPEPDMMP2ANPEPDPP4 | |
| SCHEMBL15586544 | 0.79 | PEPD (0.48) | POLBPEPDMMP2ANPEPCYP1A2 | |
| SCHEMBL3012517 | 0.79 | PEPD (0.39) | POLBPEPDMMP2ANPEPCYP1A2 | |
| SCHEMBL10138946 | 0.79 | MMP2 (0.46) | POLBPEPDMMP2ANPEPDPP4 | |
| SCHEMBL2209199 | 0.79 | GRM2 (0.36) | CYP1A2CYP2C19 | |
| SCHEMBL2209193 | 0.79 | GRM2 (0.36) | CYP1A2CYP2C19 | |
| SCHEMBL15100509 | 0.79 | — | — | |
| SCHEMBL13016442 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | POLB 3205/4885PEPD 1732/4885MMP2 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.